NeuroMab™ Anti-Alpha Synuclein Antibody, Clone NR52P
A functional antibody raised against Human Alpha Synuclein.
- Host Species:
- Rabbit
- Species Reactivity:
- Human
- Applications:
- DB; ELISA; FC; IHC; In Vitro; Cyt; In Vivo
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Formulation
Preservatives
Concentration
Purification
Purity
Endotoxin Level
Low Endotoxin < 1 EU/mg
Shipping
Storage
Research Use Only
Figure 1 α-synuclein staining in the brainstem of α-synuclein [A30P] transgenic mice.
Fresh-frozen 10 μm sagittal brain section; 40X magnification; all images under the same lighting conditions; arrows indicate Lewy neurite-like inclusions.
Figure 2 Staining of the cerebral cortex of patients with Parkinson's disease with antibodies 0017 and 0018.
(A), Alzheimer's disease patient with Parkinson's disease comorbidity (B) and progressive supranuclear palsy (PSP, tauopathy) (C); Arrowhead: Lewy body-like inclusion; Arrowhead: Lewy neurite- like inclusions.
Figure 3 Cytotoxicity of conditioned medium of recombinant α-synuclein from SHSY5Y cells on LUHMES cells.
(A), Alzheimer's disease patient with Parkinson's disease comorbidity (B) and progressive supranuclear palsy (PSP, tauopathy) (C); Arrowhead: Lewy body-like inclusion; Arrowhead: Lewy neurite- like inclusions.
Figure 4 The antibodies are capable of immunodepleting α-synuclein oligomers in the extracellular medium, thus these antibodies reduce the toxicity of α-synuclein oligomers.
(A), Alzheimer's disease patient with Parkinson's disease comorbidity (B) and progressive supranuclear palsy (PSP, tauopathy) (C); Arrowhead: Lewy body-like inclusion; Arrowhead: Lewy neurite- like inclusions.
Figure 5. After acute peripheral injection of anti-α-synuclein-antibody-blood-brain barrier shuttle module conjugates, brain α-synuclein pathology and vasculature of α-synuclein mutant A30P transgenic mice and markers of parenchymal tissue.
(A), Alzheimer's disease patient with Parkinson's disease comorbidity (B) and progressive supranuclear palsy (PSP, tauopathy) (C); Arrowhead: Lewy body-like inclusion; Arrowhead: Lewy neurite- like inclusions.
Figure 6 Confocal microscopy analysis of immunohistochemical cryosections of brain sections from patients with Parkinson's disease (same settings for all images).
(A) Antibody 0017, (B) Antibody 0018.
Figure 7 Binding of monomeric (N-terminal free (1) and N-terminal His-tagged (2)) and dimeric (3) α-synuclein to antibody 0018.
The displayed result is a titration of 5 concentrations. 1: Monomer, free N-terminal, 4.2 mg/mL, never thawed; 2: Monomer, His-tagged N-terminal, 4.8 mg/mL; 3: Dimer, free N-terminal, 1.6 mg/mL.
Publications (0)
